ReSPECT Clinical Trial’s Dr. Brenner recently participated in another Stand Up To Cancer® (SU2C) Innovation Summit, focused on advancing novel approaches for the detection and treatment of gliomas, a complex and aggressive form of brain cancer.
The summit convened leading researchers and clinicians to explore emerging science shaping the future of brain cancer care. Among the key areas of discussion was growing research demonstrating that neurons—normal brain cells—can interact directly with glioma tumors, supporting tumor growth and disease progression. These insights are reshaping how researchers think about brain cancer biology and opening new avenues for therapeutic innovation.
Understanding Neuron–Glioma Crosstalk
A major theme of the summit centered on the concept of “crosstalk” between neurons and gliomas—the biological communication that can sustain tumors and influence their behavior. Participants explored critical questions, including how these interactions contribute to tumor growth and, importantly, how disrupting or leveraging this crosstalk could lead to improved treatment strategies.
This emerging area of research underscores the importance of approaching brain cancer not only as a tumor‑centric disease, but as one deeply influenced by the surrounding neural environment.
Collaboration at the Core of Progress
Stand Up To Cancer’s collaborative research model was a central focus of the summit. By bringing together experts across disciplines and institutions, SU2C aims to accelerate progress in areas of high unmet need, including brain cancer. This approach reflects a shared belief that collaboration is essential to translating scientific discoveries into meaningful advances for patients.
Highlighting Clinical Research in Recurrent Glioblastoma
As part of the summit, Andrew Brenner, MD, PhD, joined a panel discussion focused on the ongoing development of novel approaches for brain cancer detection and treatment. During the discussion, Dr. Brenner highlighted Plus Therapeutics’ ReSPECT‑GBM clinical trial, which is evaluating a targeted radiotherapeutic approach for patients with recurrent glioblastoma.
Glioblastoma remains one of the most aggressive and difficult‑to‑treat brain cancers, and patients with recurrent disease face particularly limited treatment options. Clinical trials such as ReSPECT‑GBM play a critical role in advancing new strategies aimed at improving outcomes in this challenging setting.
Driving the Future of Brain Cancer Care
Participation in forums like the SU2C Innovation Summit reinforces Plus Therapeutics’ commitment to advancing science through collaboration, innovation, and patient‑centered research. By engaging with the broader oncology community, the company continues to support efforts that move the field forward—from foundational biological insights to the development of new clinical approaches.
Plus Therapeutics is grateful for the opportunity to contribute to these important discussions and remains focused on translating emerging science into meaningful progress for patients affected by brain cancer.
By supporting collaborative research initiatives like Stand Up To Cancer, the oncology community continues to drive the future of cancer research and care—together.
Recent Comments